Tibor Keler - Celldex Therapeutics Insider

CLDX -- USA Stock  

USD 0.42  0.0032  0.75%

Dr. Tibor Keler, Ph.D., serves as Executive Vice President and Chief Scientific Officer of Celldex Therapeutics Inc. since July 30, 2014. Since, May 2003, Dr. Keler has held a number of positions with Celldex, including a founder, Senior Vice President and Chief Scientific Officer of Celldex, from March 2008 to July 2014, and Vice President, Research and Discovery and Chief Scientific Officer, from May 2003 to March 2008. In addition, he was Senior Director of Preclinical Development and Principal Scientist at Medarex from September 1993 to March 2004. While at Medarex, he was responsible for the development of Celldex technology and products, as well as for the preclinical development and testing of numerous Medarex products now in clinical trials
Age: 58  Founder Since 2014  Ph.D    
908-200-7500  http://www.celldex.com
Keler received his Ph.D. in Microbiology from the University of Pennsylvania.

Management Efficiency

The company has return on total asset (ROA) of (23.03) % which means that it has lost $23.03 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (91.65) % meaning that it created substantial loss on money invested by shareholders.

Entity Summary

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of various immunotherapy technologies and other cancer-targeting biologics. Celldex Therapeutics, Inc. has research collaboration and license agreements with Medarex, Inc. Rockefeller University University of Southampton Amgen Inc. Amgen Fremont Seattle Genetics, Inc. Yale University and MedImmune, LLC. Celldex Therapeutics operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 192 people.Celldex Therapeutics (CLDX) is traded on BATS Exchange in USA. It is located in NEW JERSEY U.S.A and employs 192 people. Celldex Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification.

Celldex Therapeutics Leadership Team

Theresa LaVallee, Senior Vice President - Regulatory and Precision Medicine
Keith Brownlie, Director
Ronald Pepin, Chief Bus. Officer and Sr. VP
Harry Penner, Independent Director
Sam Martin, CFO, Senior Vice President
Karen Shoos, Independent Director
Gerald McMahon, Director
Sarah Cavanaugh, Vice President Investor Relations & Corporate Communications
Richard Broek, Director
Anthony Marucci, President CEO, Director
James Marino, Director
George Elston, Independent Director
Thomas Davis, Senior Vice President Chief Medical Officer
Avery Catlin, CFO, Principal Accounting Officer, Sr. VP, Treasurer and Secretary
Richard Wright, Senior Vice President Chief Commercial Officer`
Elizabeth Crowley, Senior Vice President Chief Product Development Officer
Larry Ellberger, Independent Chairman of the Board
Herbert Conrad, Independent Director
Margo HeathChiozzi, Senior Vice President - Regulatory Affairs
Tibor Keler, Founder, Chief Scientific Officer and Executive VP

Stock Performance Indicators

Did you try this?

Run Cryptocurrency Correlation Now


Cryptocurrency Correlation

Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins and exchanges
All  Next Launch Cryptocurrency Correlation

Celldex Therapeutics Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Celldex Therapeutics and China Cord Blood. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of macroaxis ideas.
Search macroaxis.com